Malta - English - Medicines Authority

beecham group plc 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - lactic acid, salicylic acid - cutaneous solution - lactic acid 15 % (w/w) salicylic acid 16.7 % (w/w) - other dermatological preparations

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g - omega-3-acid ethyl esters capsules are indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg/dl) hypertriglyceridemia. usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules and should continue this diet during treatment with omega-3-acid ethyl esters capsules. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of tg-lowering drug therapy. limitations of use: the effect of omega-3-acid ethyl esters capsules on the risk for pancreatitis has not been determined. the effect of omega-3-acid ethyl esters capsules on cardiovascular mortality and morbidity has not been determined. omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any of its components. risk summary the available data from published case reports and the pharmacovigilance database on the use of omega-3-acid ethyl esters in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, omega-3-acid ethyl esters given orally to female rats prior to mating through lactation did not have adverse effects on reproduction or development when given at doses 5 times the maximum recommended human dose (mrhd) of 4 grams/day, based on a body surface area comparison. omega-3-acid ethyl esters given orally to rats and rabbits during organogenesis was not teratogenic at clinically relevant exposures, based on body surface area comparison (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data: in female rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) beginning 2 weeks prior to mating through lactation, no adverse effects were observed at 2,000 mg/kg/day (5 times the mrhd based on body surface area [mg/m2 ]). in a dose-ranging study, female rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) beginning 2 weeks prior to mating through postpartum day 7 had decreased live births (20% reduction) and pup survival to postnatal day 4 (40% reduction) at or greater than 3,000 mg/kg/day in the absence of maternal toxicity at 3,000 mg/kg/day (7 times the mrhd based on body surface area [mg/m2 ]). in pregnant rats given oral doses of omega-3-acid ethyl esters (1,000, 3,000, or 6,000 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses at a maternally toxic dose (increased food consumption) of 6,000 mg/kg/day (14 times the mrhd based on body surface area [mg/m2 ]). in pregnant rats given oral doses of omega-3-acid ethyl esters (100, 600, or 2,000 mg/kg/day) from gestation day 14 through lactation day 21, no adverse effects were observed at 2,000 mg/kg/day (5 times the mrhd based on body surface area [mg/m2 ]). in pregnant rabbits given oral doses of omega-3-acid ethyl esters (375, 750, or 1,500 mg/kg/day) during organogenesis, no adverse effects were observed in fetuses given 375 mg/kg/day (2 times the mrhd based on body surface area [mg/m2 ]). however, at higher doses, increases in fetal skeletal variations and reduced fetal growth were evident at maternally toxic doses (reduced food consumption and body weight gain) greater than or equal to 750 mg/kg/day (4 times the mrhd), and embryolethality was evident at 1,500 mg/kg/day (7 times the mrhd). risk summary published studies have detected omega-3 fatty acids, including epa and dha, in human milk. lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. there are no data available on the effects of omega-3 fatty acid ethyl esters on the breastfed infant or on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for omega-3-acid ethyl esters and any potential adverse effects on the breastfed child from omega-3-acid ethyl esters or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. a limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters. safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

United States - English - NLM (National Library of Medicine)

ecolab inc. - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - directions for use : measure equal volume s of 4xla® base and 4xla activator into a clean dip cup/container and mix until the color is uniform through-out. do not dilute. mix only enough product for one milking of the herd. dip cups should be washed after each milking. application: pre-milking : if teats are visibly dirty, wash and dry teats with a single service towel prior to dipping. before each cow is milked, dip the teats as far up as possible. leave 4xla teat dip on teats for at least 15-30 seconds. wipe teats dry using a single service towel before milking. post-milking : immediately after milking, dip teats at least 2/3 to all their length in 4xla teat dip. allow to air dry. do not wipe. 4xla teat dip can be used as a post-di p alone, or as a pre- and post-milking teat dip. always use freshly mixed, full strength 4xla teat dip. if product in dip cup becomes visibly dirty, discard contents and fill with fresh 4xla teat dip. note 1 : if teat irritation occurs, discontinue use until irritation subsides.

United States - English - NLM (National Library of Medicine)

ecolab inc. - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at), salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - directions: important: do not further dilute with water or mix with any other teat dips. if product in dip cup becomes visibly dirty, discard contents and replenish with fresh product. do not reuse or return any unused product to the original container. udder prep: when using an udder wash step before milking, make sure to wash teats with appropriate udder wash solution using proper cleaning procedures. teats should then be dried with single-service towels. directions for teat dipping pre-milk dipping: before each cow is milked, and using fresh masticare pre & post, dip each teat full-length into the teat dip cup. wipe teats after dipping using single-service towels to avoid contamination of milk. post-milk dipping: using fresh masticare pre & post, dip each teat full-length into the teat dip cup. do not wipe. allow to air dry. do not turn cows out in freezing weather until the product is completely dry. expanded usage: when freshening cows, begin dipping teats twice daily for about 10 days before calvin

United States - English - NLM (National Library of Medicine)

brown dairy equipment co., inc - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - for:  ready-to-use teat dip:          1500 ppm chlorine dioxide, 5% glycerine - mix 10-parts cd-10 "a" concentrate activator to 113 parts of potable water! - add 5-parts cd-10 "b" concentrated base. - mix thoroughly! for:  ready-to-use teat dip:          1500 ppm chlorine dioxide, 10% glycerine - mix 21-parts cd-10 "a" concentrate activator to 100 parts of potable water! - add 7-parts cd-10 "b" concentrated base - mix thoroughly!

United States - English - NLM (National Library of Medicine)

ecolab inc. - lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at) - directions for use: measure equal volumes of aztec gold base and aztec gold activator into a clean dip cup/container and mix until the color is uniform throughout. do not dilute. mix only enough product for one milking of the herd. dip cups should be washed after each milking. application: pre-milking: if teats are visibly dirty, wash and dry teats with a single service towel prior to dipping. before each cow is milked, dip the teats as far up as possible. leave aztec gold teat dip on teats for at least 15-30 seconds. wipe teats dry using a single service towel before milking. post-milking: immediately after milking, dip teats at least 2/3 their length in aztec gold teat dip. allow to air dry. do not wipe. aztec gold teat dip can be used as a post-dip alone, or as a pre and post-milking teat dip. always use freshly mixed, full strength aztec gold teat dip. if product in dip cup becomes visibly dirty, discard contents and fill with fresh aztec gold teat dip. note 1: if teat irritation occurs, discontin

United States - English - NLM (National Library of Medicine)

borion - lactic acid, l- (unii: f9s9ffu82n) (lactic acid, l- - unii:f9s9ffu82n) - see symptoms on front panel. relieves pain and stiffness from muscular overexertion * stop use and ask a doctor if symptoms persist for more than 3 days or worsen.

Ireland - English - HPRA (Health Products Regulatory Authority)

new haven pharma (uk) limited - acetylsalicylic acid - prolonged-release capsule, hard - 162.5 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Canada - English - Health Canada

pendopharm division of pharmascience inc - acetylsalicylic acid - tablet (delayed-release) - 325mg - acetylsalicylic acid 325mg - salicylates

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - lactic acid; salicylic acid - paint - 150mg/1gram ; 167mg/1gram